TY - JOUR AU - Addeo, Alfredo AU - Banna, Giuseppe Luigi AU - Friedlaender, Alex PY - 2019 TI - Stepping in the right direction but still some ways to go JF - Translational Cancer Research; Vol 8, Supplement 6 (December 20, 2019): Translational Cancer Research Y2 - 2019 KW - N2 - Over the last few years we have witnessed substantial advances in systemic treatment of non-small cell lung cancer (NSCLC) patients harboring anaplastic lymphoma kinase gene rearrangements (ALK+ NSCLC) (ref). Multiple ALK inhibitors (ALKi) have been approved (alectinib, lorlatinib, brigatinib, ceritinib, crizotinib). Despite the survival benefit of all of these drugs, all patients with ALK+ NSCLC will inevitably progress at some point during their treatment (my review). Given the increased number of therapeutic options, understanding the resistance mechanism appears to be increasingly important. UR - https://tcr.amegroups.org/article/view/30863